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ABSTRACT 
Background : ECT, though not favoured in the West for treating schizophrenia, is 
regularly practiced in India for this indication, particularly in poorly responding/treatment 
resistant cases.Therefore, its role in treatment-resistant schizophrenia is a subject of 
systematic investigation. 
Aim : To compare the effectiveness and safety of Electroconvulsive therapy (ECT) in a 
group of treatment-resistant schizophrenia patients with a control group. 
Method : Eligible and consenting patients were randomly allocated to the ECT or 
Sham ECT groups. Both received antipsychotic drugs.Twenty-five patients completed 
the study (ECT, n= IS; Sham ECT, n= 10).The study was conducted in a double-blind 
manner. Clinical change was assessed weekly with BPRS, CGI and adverse event 
measures.ANOVA for repeated measures and other post-hoc comparisons were used 
for data analysis. 
Results: ECT treated patients improved significantly over successive weeks (p<0.002) 
after 6 ECTs, whereas the group receiving sham-ECT did not In both the groups, 
however, CGI scores did not change significantly, suggesting a dissociated response 
pattern. ECT was associated with greater relief among carers and lower re-
hospitalization. 
Conclusion : ECT augmentation may well have a significant impact on the clinical 
course of patients with treatment resistance schizophrenia. It is unclear, but possible, 
that these changes may be reinforced and maintained by maintenance ECTs. Replication 
of the present investigation and further studies on maintenance ECT would be 
rewarding. 
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INTRODUCTION 
Traditionally, schizophrenia has been 
conceived as a behavioural syndrome 
characterized by early onset and chronic, 
unremitting course resulting in deterioration. 
These defining characteristics indicate that 
chronicity is central to the diagnosis of 
schizophrenia. Even in the acute phase of 
the illness, as high as 40% of 
pharmacologically treated patients continue 
to exhibit moderate to severe psychotic 
symptoms, and nearly 10% of them do not 
show any improvement (APA, 1994). Thus, 
the patients with schizophrenia are potentially 
chronic but therapy-resistant as well. In 
order to define this group, a set of 
operational criteria has been introduced 
(Kane et al, 1988). 
Currently, antipsychotics drugs are 
considered to be the first hnt treatment in 
schizophrenia. Despite good compliance 
and adequate treatment, upto 25% of these 
patients remain partially or totally 
unresponsive to antipsychotic drug treatment 
(Brenner et al, 1990). They may require 
higher dose, switch to another antipsychotic 
of a different class or use of adjunctive 
treatments like lithium, benzodiazepines, 
antidepressants or ECT (Morrison, 1996). 
Electroconvulsive therapy (ECT) was seen 
as a promising treatment for schizophrenia. 
Due to several reasons, it fell out of favour. 
It has been claimed that the results of 
controlled studies were negative (Taylor and 
Flemminger, 1980), that ECT had litde 
influence on the course and outcome of 
schizophrenia and that those with chronic 
symptoms rarely improved. Further, 
neuroleptic drugs were found to be at least 
as effective as ECT in schizophrenia (May 
et al., 1976) and maintenance ECT was not 
shown to be effective. The strong adverse 
public opinion has also led to its infrequent 
use. 
On the other hand, Christison et al 
(1991) opined that ECT continued to have 
a place in the treatment of some patients 
of schizophrenia and that the role of ECT 
for patients with chronic symptoms was less 
clear. Therefore, use of ECT in neuroleptic-
resistant patients was debatable and that 
double blind controlled investigations were 
necessary to resolve this issue. The present 
study was thus designed to detetmine the 
effect of ECT in treatment-resistant 
schizophrenia. 
MATERIAL AND METHODS 
Patient selection 
Forty-five consecutive OPD patients 
suffering from schizophrenia (DSM IV) 
(American Psychiatric Association, 1994) 
and treatment refractoriness (Kane et al., 
1988) were selected for the study. Two 
clinicians independently (UG & UK) 
confirmed the diagnosis. All the patients 
were screened for persistent illness of five 
or more year's duration with no satisfactory 
social and occupational functioning. Where 
possible, it was also verified through 
prescriptions and hospital records that each 
patient had at least three periods of treatment 
in the preceding five years with neuroleptics 
of at least two different chemical classes, 
at doses equivalent to or greater than 1000 
mg/day of Chlorpromazine equivalent for 
a period of 6 weeks each without significant 
relief. The selected patients were admitted 
and pre-anaesthetic assessment was done in 
the department of Anaesthesia. 
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Rating instruments 
At this baseline, all the patients were 
administered Brief Psychiatric Rating Scale 
(BPRS) (Overall and Gorham 1962) for 
screening in keeping with the criteria by 
Kane et al (1988) and Clinical Global 
Impression Scale (CGI) prior to the patients 
| being scheduled for real or sham-ECT 
treatment. Those with total BPRS less than 
45 or CG1-S < 4 were excluded from the 
study. In addition, all patients were rated on 
standard movement disorder rating scales 
(EPS and TD), visual analogue for subjective 
comfort with treatment as well as rater 
based assessment of patients' tolerability of 
drugs and/or ECT. 
Informed consent procedure 
The purpose and the design of the study 
were explained to the patients and the 
member(s) of the family, including the fact 
that the patient may or may not receive the 
ECT. Consent for general anaesthesia and 
ECT was obtained from the patients, or, in 
case the patient was unable to give consent, 
from a responsible member of the family. 
The relatives were also educated about the 
available treatment alternatives. The patients 
f and the consenting relative(s) were informed 
that they could withdraw the consent at any 
point if they desired so, without adversely 
affecting care. 
Anaesthesia and ECT procedures 
All the selected patients were scheduled 
for ECT and were kept fasting overnight. 
In the ECT room, intravenous line was 
secured using a 22 gauge indwelling cannula 
on the dorsum of hand. Bitemporal leads 
were applied and the parameters on the 
ECT machine (MECTA-SR1 apparatus) were 
selected to deliver a brief pulse intensity of 
50% to 200% of seizure threshold. After 
the parameters were adjusted, the psychiatrist 
left the room and the patients thereafter 
were managed by the anaesthesia team. 
Using a random number table, the patients 
were randomly allocated to treatment groups 
by anaesthesia team and none of the 
psychiatrists knew the blind. 
Irrespective of the group allocation, 
anaesthesia was induced in all the patients 
with injection thiopentone 4-5 mg/Kg. The 
patients in the study group were administered 
injection succinylcholine 0.6mg/kg and were 
manually ventilated with 100% oxygen using 
face mask with Magill's circuit connected to 
Boyle's anaesthesia apparatus. When the 
neuromuscular blockade had set in, ECT 
was given as per the set parameters and 
seizures were recorded. The seizure duration 
was determined by the interval between the 
ECT stimulus delivery and the last spike in 
the EEG recording. To ensure seizure 
duration of 25 seconds, die seizures were 
recorded by two electrodes placed bilaterally 
with unipolar frontal EEG lead. In the 
control group, ECT was not given, however, 
after induction of anaesthesia manual 
ventilation was done till the patient returned 
to adequate spontaneous respiration. The 
patients were shifted out of the ECT room 
when they were conscious, breathing 
spontaneously and obeying verbal commands. 
Antipsychotic drug treatment and 
rescue medications 
All the patients were given chlorpromazine 
up to 1000 mg/day. The dose was titrated 
in terms of clinical response and side 
effects. Extrapyramidal side effects, if any, 
were managed by the trihexiphenedyl up to 
6 mg/day. In uncontrolled agitated psychotic 
patients, intravenous diazepam and 
promethazine were also used as and when 
required. To facilitate compliance to the 
treatment regimen, the drugs were supplied 
free of cost. 
The patients were monitored for efficacy 
of treatment modalities with BPRS and 
CGI and side effects if any were recorded. 
RESULTS 
Of the 45 patients who fulfilled the 
eligibility criterion, only 31 gave written 
informed consent. Five patients did not 
complete the study; one more patient was 
excluded as her diagnosis changed to 
schizoaffective disorder. Thus, the data of 
only 25 patients who completed the study 
were subjected to data analysis. 
Both the groups received an average of 
about 500 mg/day of chlorpromazine 
equivalents at the baseline. The two groups 
were comparable in respect of variables 
such as age, sex, marital status, occupational 
status, socioeconomic status, education, and 
presence/ absence of stressor (Table 1). 
TABLE I: Sociodemographic variables 
in two groups (ECT and Sham ECT) 
Age (Years) 
Male 
Female 
Marital status 
Stressor Present 
ECT 
n=15 
29.8+8.54 
60% 
40% 
2/15 
20% 
Sham 
ECT n=10 
29.1+5.7 
70% 
30% 
3/10 
20% 
The two groups did not also differ in 
respect of the clinical variables such as past 
history of ECT, subtype, expressed emotion 
in the family, body type, general assessment 
of functioning scale score and presence of 
first rank symptoms (Table 2). 
TABLE 2: General clinical characteristics of two groups (ECT and Sham ECT) 
Past h/o ECT 
Insidious onset 
Mean duration of illness 
Age of onset 
EE (Present) 
GAF score 
FRS 
ECT n=15 
2 
53% 
7.6 years 
22.13+7.3 
46.6% 
25.53 
60% 
years 
Sham ECT n=10 
Nil 
70% 
6.9 years 
22.2+4.8 years 
60% 
26.4 
80% 
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Primary measure: Total BPRS (see Table 
3 for details) 
In the present study, 18 items BPRS was 
used; each item was rated on a scale of 1 
to 7. Out of the maximum possible score 
of 126, a score of 45 or more was 
considered to be of the inclusion criteria 
in the trial. Improvement was defined as a 
20% decrease in BPRS total score plus 
either post treatment CGI rating mildly ill 
(<3) or a post treatment score of 35 or less 
on BPRS. 
Since the patients were assessed at 
baseline and later weekly, we analysed the 
data set using ANOVA for repeated measure 
(AN OVA - RM) to evaluate the weekly 
change on BPRS. 
TABLE 3: Total BPRS from baseline till week 4 between ECT and Sham-ECT groups of patients 
Groups  Observation on the BPRS for consecutive 4 weeks 
Week 0 Week 1 Week 2  Week 3  Week 4 
Group 1 
Group II 
55 ± 7.2 
50.1 ± 3.9 
52.6 ± 7.8 
45.6 ± 5.8 
48.6 ± 7.9 
42.6 ± 7 
47.6± 8.6 
42.2 ± 8 
44 ± 7.6 
40.4 ± 10 
The ECT group has shown significant 
decline of scores on BPRS as seen in Table 
3 (ANOVA - RM; MS between 
groups=247.7; MS within groups=61.6; 
F=4.5; d.f.= 4, 74; p<0.002). Similar 
comparison in the sham-ECT group does 
not reveal any significant difference 
(ANOVA-RM; MS between groups=45.9; 
MS within groups=63.2; F=0.72; d.f.=3, 39; 
p>0.542). Further post-hoc comparisons 
across the weeks reveal that the improvement 
occurs with effect from the second week, 
after 6 HCTs arc administered. 
Secondary Measures: Clinical Global 
Impression (CGI) (Table 4) 
Table 4 shows total CGI between 
baseline and week 4 in ECT and sham-
ECT groups of patients. There arc no 
significant differences between the groups. 
TABLE 4 : Total CGI between baseline 
and week 4 in ECT and sham-ECT 
Group  Baseline Week 4 
ECT 4.9 
Sham-ECT 4.6 
4.13 
3.8 
NS 
NS 
Other secondary measures included rescue 
medication, total daily antipsychotics 
received, subjective satisfaction with the 
treatment received. The two groups received 
comparable doses of rescue drugs, i.e., 
parenteral diazepam or promethazine. Their 
daily oral Chlorpromazine equivalents were 
also comparable. However, the relatives 
favoured ECT treatment for greater comfort 
and satisfaction. Finally, the rates of re-
hospitalization were lower for ECT group 
(20%) as opposed to sham-ECT (70%). 
Discussion 
The principal finding of this study is that 
ECT-treated patients improved significandy 
on BPRS from week 2 onwards. There has 
been a case report of ECT augmenting 
Clozapine in treatment resistant 
schizophrenia, after the effect of the latter 
appeared to have been lost (Safferman and 
Munne, 1992). These authors found that the 
combination of ECT and Clozapine was 
safe and effective and suggested that further 
controlled studies were required to work out 
the precise role of the combination in the 
context of treatment resistant schizophrenia. 
The present investigation is an important 
step in that direction. Hopefully, this might 
stimulate independent replication elsewhere. 
In his review, Meltzer (1992) justifiably 
listed ECT as a treatment modality for 
therapy-resistant schizophrenia. A positive 
treatment effect of ECT in two clozapine 
unresponsive schizophrenic patients was 
described by Sajatovic and Meltzer (1993). 
Our study provides objective evidence that 
indeed ECT would favourably influence the 
psychopathology of treatment resistant 
schizophrenia patients. It is unrealistic to 
expect an immediate response with ECT. 
Clearly, the changes are detected after the 
6th ECT, at the completion of second 
week. 
The sham-ECT group did not have any 
significant symptom change. Hence, we 
would restrict further discussion to the ECT 
group. 
Many studies in the past, if only in the 
context of treatment of schizophrenia, have 
reported similar treatment effects on the 
BPRS (Aggarwal and Winny, 1985; Abraham 
and Kulhara, 1987; Sajatovic and Meltzer, 
1993). 
The BPRS data favour the argument that 
ECT did have an augmenting effect on the 
ongoing neuroleptic drug therapy, at least 
transiently. Since the study had a design of 
random allocation of patients to treatment 
groups and is conducted double blind, the 
ECT-group would not have improved if 
they continued to receive drugs alone. While 
discussing their results of uncontrolled, 
open trial of ECT, Sajatovic and Meltzer 
(1993) had observed, "..the possibility that 
ECT procedure including anesthesia may have 
contributed to the improvement can only be studied 
with a sham-ECT control group." The present 
study has accomplished just this mission. 
In a study like this, schizoaffective patients 
are better avoided (janakiramaiah and 
Subbakrishna, 1981). Affective symptoms 
(DSS) in schizophrenia may predict good 
outcome (Salzman, 1980; Wells, 1973). 
However, Sajatovic and Meltzer (1993) 
maintained that the improvement had not 
been simply attributable to improvement in 
mood symptoms. Even Dodwell and 
Goldberg (1999) failed to notice any 
therapeutic edge of ECT in schizoaffective 
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disorder. In the present study, we stayed 
clear of the schizoaffective disorder to 
avoid any noise. 
A close look at CGI data would indicate 
that the clinical problem of schizophrenia, 
apparently, persists, beyond symptom 
resolution. Of course no clinician expects 
massive treatment effect of any agent on 
this group. These patients are chronically ill 
and drug treatment alone cannot take care 
of the deficits. One can expect, however, 
to detect a definite but small magnitude of 
clinical change. If the schizophrenia group 
treated with ECT did not improve in the 
first place, it would be unwise to pursue this 
research any further. 
Clinicians would readily agree that a 
course of 12 to 18 ECTs would not restore 
most of these therapy resistant cases to 
normal or near normal in psycho-social 
functioning. For this to happen, one would 
have to combine non-pharmacological 
approaches, including behaviour modification 
and cognitive therapy. In addition, one has 
to work with the families and significant 
others for effective intervention of negative 
emotional climate. However, we have two 
patients whose CGI came down on 3 or 
less. It indicates the possibility that ECT 
treatment, in a significant minority, would 
produce a faster relief than expected. Again, 
a large sample would be able to detect this 
change. 
The secondary measures include: family's 
acceptance of the treatment and frequency 
of re-hospitalization. Our data suggests that 
only 20% of cases that received ECT were 
rc-hospitalized within 6 months, as compared 
to 70% in the sham-ECT group. A larger 
sample size would have ensured a more 
robust treatment effect. It would be 
interesting to compare the levels of 
extrapyramidal side effects between the two 
groups. There is some evidence suggesting 
that patients treated with ECT may 
experience less EPS (Goswami et al, 1989). 
ECT was a well-accepted treatment as 
rated by the patients' relatives. It is possible 
that there is a cross-cultural variation in 
public perception and sensitivity. ECT and 
clozapine are both difficult choices to make 
in India. Several factors may render ECT 
as an attractive treatment alternative: 1) lack 
of long term side effects, 2) lower dose of 
concomitant neuroleptic medication, 3) 
reduction in the duration of hospital stay 
and 4) cost. 
Social dimensions of change are linked 
to the higher level of acceptance/comfort 
of the relatives associated with ECT. In 
short term analysis, more than this would 
not be realistic. An independent replication 
and the follow up information on this issue 
are vital to the state of ECT research in 
the context of treatment-resistant 
schizophrenia. 
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